SIRT6 and cancer: In HER2-positive tumors, the overexpression of SIRT6 promotes metastasis and relapse by repressing TBX3 through H3K9ac deacetylation, which confers cancer stem cell–like traits, dormancy, and poor relapse-free survival [42].